UNSPSC 51434204: Rescinnamine

This classification denotes an antihypertensive agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q6W1F7DJ2D. European Medicines Agency schedules Rescinnamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10285MIG. Rescinnamine generally arises in the molecular formula C35H42N2O9.

UNSPSC 51434204 Rescinnamine, a Commodity code, represents a narrow pharmaceutical product class that state and local governments purchase as part of broader emergency medical and health system supply chains. Recent solicitations show that the code is being applied to procurement of advanced life support medications and generic pharmaceutical products, though the specific alkaloid rescinnamine itself does not appear in recent opportunity notices. State and local buyers under this code include city fire and rescue departments, state health and human services agencies, and cooperative purchasing alliances serving multi-state government networks. Work solicited ranges from single-unit advanced life support medication orders for emergency medical services to large-scale generic pharmaceutical and over-the-counter product contracts distributed through authorized wholesale channels to multiple government facilities across participating jurisdictions.

Geographic activity centers on Florida and Minnesota, with multi-state reach through cooperative purchasing. The City of Tampa's Purchasing Department issued IFB 26P00188 for Advanced Life Support Medications (Labetalol, Epinephrine, Adenosine, and Diltiazem) for Tampa Fire Rescue with a response deadline of April 8, 2026 and an estimated contract value of $40,000.00, featuring a 5 percent Small Local Business Enterprise bid discount not to exceed $10,000. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline, requiring vendor participation through AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, or Morris & Dickson as authorized wholesalers and a two-year contract term effective July 1, 2026. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs, an exploratory phase preceding formal procurement that does not establish binding timelines or award values.